Author: "Schiavon, F" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Schiavon, F"' showing total 349 results

Start Over Author "Schiavon, F"

349 results on '"Schiavon, F"'

1. AB1261 AVACOPAN IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS: MULTICENTER PROSPECTIVE REAL-LIFE STUDY ON EFFICACY, SAFETY, AND IMPACT ON QUALITY OF LIFE

Author: Treppo, E., primary, De Martino, M., additional, Bello, F., additional, Padoan, R., additional, Monti, S., additional, Moroni, L., additional, Affatato, S., additional, Conticini, E., additional, Galli, E., additional, Marvisi, C., additional, Tombetti, E., additional, Frediani, B., additional, Alberici, F., additional, Dagna, L., additional, Delvino, P., additional, Schiavon, F., additional, Emmi, G., additional, Salvarani, C., additional, Isola, M., additional, and Quartuccio, L., additional
Published: 2024
Full Text: View/download PDF

2. A new model for NVSS galaxy catalogue using the redshift distribution and halo minimum mass

Author: Marcos-Caballero, A., Vielva, P., Martinez-Gonzalez, E., Finelli, F., Gruppuso, A., and Schiavon, F.
Subjects: Astrophysics - Cosmology and Extragalactic Astrophysics
Abstract: In the present paper we study the radio sources in the NRAO VLA SKY Survey (NVSS) analysing its power spectrum and galaxy distribution. There is a discrepancy between the theoretical models in the literature and the data at large scales. A new model for NVSS is proposed combining the power spectrum data from NVSS and the galaxy distribution from the Combined EIS-NVSS Survey Of Radio Sources (CENSORS). Taken into account these two data sets the differences in the power spectrum at large scales are reduced, but there is still some tension between the two data sets. Different models are compared using Bayesian evidence. A model for the galaxy distribution based on a gamma function provides a higher evidence against other models proposed in the literature. In addition, the effect of primordial non-Gaussianity has been also considered. The 2-sigma constraints on the local non-Gaussian f_NL parameter are -43 < f_NL < 142., Comment: 8 pages, 5 figuresm submitted to MNRAS
Published: 2013

3. Planck 2013 results. XIX. The integrated Sachs-Wolfe effect

Author: Planck Collaboration, Ade, P. A. R., Aghanim, N., Armitage-Caplan, C., Arnaud, M., Ashdown, M., Atrio-Barandela, F., Aumont, J., Baccigalupi, C., Banday, A. J., Barreiro, R. B., Bartlett, J. G., Bartolo, N., Battaner, E., Benabed, K., Benoît, A., Benoit-Lévy, A., Bernard, J. -P., Bersanelli, M., Bielewicz, P., Bobin, J., Bock, J. J., Bonaldi, A., Bonavera, L., Bond, J. R., Borrill, J., Bouchet, F. R., Bridges, M., Bucher, M., Burigana, C., Butler, R. C., Cardoso, J. -F., Catalano, A., Challinor, A., Chamballu, A., Chiang, H. C., Chiang, L. -Y, Christensen, P. R., Church, S., Clements, D. L., Colombi, S., Colombo, L. P. L., Couchot, F., Coulais, A., Crill, B. P., Curto, A., Cuttaia, F., Danese, L., Davies, R. D., Davis, R. J., de Bernardis, P., de Rosa, A., de Zotti, G., Delabrouille, J., Delouis, J. -M., Désert, F. -X., Dickinson, C., Diego, J. M., Dolag, K., Dole, H., Donzelli, S., Doré, O., Douspis, M., Dupac, X., Efstathiou, G., Enßlin, T. A., Eriksen, H. K., Fergusson, J., Finelli, F., Forni, O., Fosalba, P., Frailis, M., Franceschi, E., Frommert, M., Galeotta, S., Ganga, K., Génova-Santos, R. T., Giard, M., Giardino, G., Giraud-Héraud, Y., González-Nuevo, J., Górski, K. M., Gratton, S., Gregorio, A., Gruppuso, A., Hansen, F. K., Hanson, D., Harrison, D., Henrot-Versillé, S., Hernández-Monteagudo, C., Herranz, D., Hildebrandt, S. R., Hivon, E., Ho, S., Hobson, M., Holmes, W. A., Hornstrup, A., Hovest, W., Huffenberger, K. M., Ilić, S., Jaffe, A. H., Jaffe, T. R., Jasche, J., Jones, W. C., Juvela, M., Keihänen, E., Keskitalo, R., Kisner, T. S., Knoche, J., Knox, L., Kunz, M., Kurki-Suonio, H., Lagache, G., Lähteenmäki, A., Lamarre, J. -M., Langer, M., Lasenby, A., Laureijs, R. J., Lawrence, C. R., Leahy, J. P., Leonardi, R., Lesgourgues, J., Liguori, M., Lilje, P. B., Linden-Vørnle, M., López-Caniego, M., Lubin, P. M., Macías-Pérez, J. F., Maffei, B., Maino, D., Mandolesi, N., Mangilli, A., Marcos-Caballero, A., Maris, M., Marshall, D. J., Martin, P. G., Martínez-González, E., Masi, S., Massardi, M., Matarrese, S., Matthai, F., Mazzotta, P., Meinhold, P. R., Melchiorri, A., Mendes, L., Mennella, A., Migliaccio, M., Mitra, S., Miville-Deschênes, M. -A., Moneti, A., Montier, L., Morgante, G., Mortlock, D., Moss, A., Munshi, D., Naselsky, P., Nati, F., Natoli, P., Netterfield, C. B., Nørgaard-Nielsen, H. U., Noviello, F., Novikov, D., Novikov, I., Osborne, S., Oxborrow, C. A., Paci, F., Pagano, L., Pajot, F., Paoletti, D., Partridge, B., Pasian, F., Patanchon, G., Perdereau, O., Perotto, L., Perrotta, F., Piacentini, F., Piat, M., Pierpaoli, E., Pietrobon, D., Plaszczynski, S., Pointecouteau, E., Polenta, G., Ponthieu, N., Popa, L., Poutanen, T., Pratt, G. W., Prézeau, G., Prunet, S., Puget, J. -L., Rachen, J. P., Racine, B., Rebolo, R., Reinecke, M., Remazeilles, M., Renault, C., Renzi, A., Ricciardi, S., Riller, T., Ristorcelli, I., Rocha, G., Rosset, C., Roudier, G., Rowan-Robinson, M., Rubiño-Martín, J. A., Rusholme, B., Sandri, M., Santos, D., Savini, G., Schaefer, B. M., Schiavon, F., Scott, D., Seiffert, M. D., Shellard, E. P. S., Spencer, L. D., Starck, J. -L., Stolyarov, V., Stompor, R., Sudiwala, R., Sunyaev, R., Sureau, F., Sutter, P., Sutton, D., Suur-Uski, A. -S., Sygnet, J. -F., Tauber, J. A., Tavagnacco, D., Terenzi, L., Toffolatti, L., Tomasi, M., Tristram, M., Tucci, M., Tuovinen, J., Umana, G., Valenziano, L., Valiviita, J., Van Tent, B., Varis, J., Viel, M., Vielva, P., Villa, F., Vittorio, N., Wade, L. A., Wandelt, B. D., White, M., Xia, J. -Q., Yvon, D., Zacchei, A., and Zonca, A.
Subjects: Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract: Based on CMB maps from the 2013 Planck Mission data release, this paper presents the detection of the ISW effect, i.e., the correlation between the CMB and large-scale evolving gravitational potentials. The significance of detection ranges from 2 to 4 sigma, depending on which method is used. We investigate three separate approaches, which cover essentially all previous studies, as well as breaking new ground. (i) Correlation of the CMB with the Planck reconstructed gravitational lensing potential (for the first time). This detection is made using the lensing-induced bispectrum; the correlation between lensing and the ISW effect has a significance close to 2.5 sigma. (ii) Cross-correlation with tracers of LSS, yielding around 3 sigma significance, based on a combination of radio (NVSS) and optical (SDSS) data. (iii) Aperture photometry on stacked CMB fields at the locations of known large-scale structures, which yields a 4 sigma signal when using a previously explored catalogue, but shows strong discrepancies in amplitude and scale compared to expectations. More recent catalogues give more moderate results, ranging from negligible to 2.5 sigma at most, but with a more consistent scale and amplitude, the latter being still slightly above what is expected from numerical simulations within LCMD. Where they can be compared, these measurements are compatible with previous work using data from WMAP, which had already mapped these scales to the limits of cosmic variance. Planck's broader frequency coverage confirms that the signal is achromatic, bolstering the case for ISW detection. As a final step we use tracers of large-scale structure to filter the CMB data, presenting maps of the ISW temperature perturbation. These results provide complementary and independent evidence for the existence of a dark energy component that governs the current accelerated expansion of the Universe., Comment: 24 pages, 11 figures. This paper is one of a set associated with the 2013 data release from Planck. Updated version: minor corrections have been made
Published: 2013
Full Text: View/download PDF

4. Planck 2013 results. XII. Component separation

Author: Planck Collaboration, Ade, P. A. R., Aghanim, N., Armitage-Caplan, C., Arnaud, M., Ashdown, M., Atrio-Barandela, F., Aumont, J., Baccigalupi, C., Banday, A. J., Barreiro, R. B., Bartlett, J. G., Battaner, E., Benabed, K., Benoît, A., Benoit-Lévy, A., Bernard, J. -P., Bersanelli, M., Bielewicz, P., Bobin, J., Bock, J. J., Bonaldi, A., Bonavera, L., Bond, J. R., Borrill, J., Bouchet, F. R., Boulanger, F., Bridges, M., Bucher, M., Burigana, C., Butler, R. C., Cardoso, J. -F., Catalano, A., Challinor, A., Chamballu, A., Chary, R. -R., Chen, X., Chiang, L. -Y, Chiang, H. C., Christensen, P. R., Church, S., Clements, D. L., Colombi, S., Colombo, L. P. L., Couchot, F., Coulais, A., Crill, B. P., Cruz, M., Curto, A., Cuttaia, F., Danese, L., Davies, R. D., Davis, R. J., de Bernardis, P., de Rosa, A., de Zotti, G., Delabrouille, J., Delouis, J. -M., Désert, F. -X., Dickinson, C., Diego, J. M., Dole, H., Donzelli, S., Doré, O., Douspis, M., Dunkley, J., Dupac, X., Efstathiou, G., Enßlin, T. A., Eriksen, H. K., Falgarone, E., Finelli, F., Forni, O., Frailis, M., Fraisse, A. A., Franceschi, E., Galeotta, S., Ganga, K., Giard, M., Giardino, G., Giraud-Héraud, Y., González-Nuevo, J., Górski, K. M., Gratton, S., Gregorio, A., Gruppuso, A., Hansen, F. K., Hanson, D., Harrison, D., Helou, G., Henrot-Versillé, S., Hernández-Monteagudo, C., Herranz, D., Hildebrandt, S. R., Hivon, E., Hobson, M., Holmes, W. A., Hornstrup, A., Hovest, W., Huey, G., Huffenberger, K. M., Jaffe, T. R., Jaffe, A. H., Jewell, J., Jones, W. C., Juvela, M., Keihänen, E., Keskitalo, R., Kisner, T. S., Kneissl, R., Knoche, J., Knox, L., Kunz, M., Kurki-Suonio, H., Lagache, G., Lähteenmäki, A., Lamarre, J. -M., Lasenby, A., Laureijs, R. J., Lawrence, C. R., Jeune, M. Le, Leach, S., Leahy, J. P., Leonardi, R., Lesgourgues, J., Liguori, M., Lilje, P. B., Linden-Vørnle, M., López-Caniego, M., Lubin, P. M., Macías-Pérez, J. F., Maffei, B., Maino, D., Mandolesi, N., Marcos-Caballero, A., Maris, M., Marshall, D. J., Martin, P. G., Martínez-González, E., Masi, S., Matarrese, S., Matthai, F., Mazzotta, P., Meinhold, P. R., Melchiorri, A., Mendes, L., Mennella, A., Migliaccio, M., Mikkelsen, K., Mitra, S., Miville-Deschênes, M. -A., Moneti, A., Montier, L., Morgante, G., Mortlock, D., Moss, A., Munshi, D., Naselsky, P., Nati, F., Natoli, P., Netterfield, C. B., Nørgaard-Nielsen, H. U., Noviello, F., Novikov, D., Novikov, I., O'Dwyer, I. J., Osborne, S., Oxborrow, C. A., Paci, F., Pagano, L., Pajot, F., Paladini, R., Paoletti, D., Partridge, B., Pasian, F., Patanchon, G., Pearson, T. J., Perdereau, O., Perotto, L., Perrotta, F., Pettorino, V., Piacentini, F., Piat, M., Pierpaoli, E., Pietrobon, D., Plaszczynski, S., Platania, P., Pointecouteau, E., Polenta, G., Ponthieu, N., Popa, L., Poutanen, T., Pratt, G. W., Prézeau, G., Prunet, S., Puget, J. -L., Rachen, J. P., Reach, W. T., Rebolo, R., Reinecke, M., Remazeilles, M., Renault, C., Renzi, A., Ricciardi, S., Riller, T., Ristorcelli, I., Rocha, G., Rosset, C., Roudier, G., Rowan-Robinson, M., Rubiño-Martín, J. A., Rusholme, B., Salerno, E., Sandri, M., Santos, D., Savini, G., Schiavon, F., Scott, D., Seiffert, M. D., Shellard, E. P. S., Spencer, L. D., Starck, J. -L., Stompor, R., Sudiwala, R., Sunyaev, R., Sureau, F., Sutton, D., Suur-Uski, A. -S., Sygnet, J. -F., Tauber, J. A., Tavagnacco, D., Terenzi, L., Toffolatti, L., Tomasi, M., Tristram, M., Tucci, M., Tuovinen, J., Türler, M., Umana, G., Valenziano, L., Valiviita, J., Van Tent, B., Varis, J., Viel, M., Vielva, P., Villa, F., Vittorio, N., Wade, L. A., Wandelt, B. D., Wehus, I. K., Wilkinson, A., Xia, J. -Q., Yvon, D., Zacchei, A., and Zonca, A.
Subjects: Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract: Planck has produced detailed all-sky observations over nine frequency bands between 30 and 857 GHz. These observations allow robust reconstruction of the primordial cosmic microwave background (CMB) temperature fluctuations over nearly the full sky, as well as new constraints on Galactic foregrounds. This paper describes the component separation framework adopted by Planck. We test four foreground-cleaned CMB maps derived using qualitatively different component separation algorithms. The quality of our reconstructions is evaluated through detailed simulations and internal comparisons, and shown through various tests to be internally consistent and robust for CMB power spectrum and cosmological parameter estimation up to l = 2000. The parameter constraints on LambdaCDM cosmologies derived from these maps are consistent with those presented in the cross-spectrum based Planck likelihood analysis. We choose two of the CMB maps for specific scientific goals. We also present maps and frequency spectra of the Galactic low-frequency, CO, and thermal dust emission. The component maps are found to provide a faithful representation of the sky, as evaluated by simulations. For the low-frequency component, the spectral index varies widely over the sky, ranging from about beta = -4 to -2. Considering both morphology and prior knowledge of the low frequency components, the index map allows us to associate a steep spectral index (beta < -3.2) with strong anomalous microwave emission, corresponding to a spinning dust spectrum peaking below 20 GHz, a flat index of beta > -2.3 with strong free-free emission, and intermediate values with synchrotron emission., Comment: 31 pages, 32 figures, submitted to A&A
Published: 2013
Full Text: View/download PDF

5. Planck 2013 results. I. Overview of products and scientific results

Author: Planck Collaboration, Ade, P. A. R., Aghanim, N., Alves, M. I. R., Armitage-Caplan, C., Arnaud, M., Ashdown, M., Atrio-Barandela, F., Aumont, J., Aussel, H., Baccigalupi, C., Banday, A. J., Barreiro, R. B., Barrena, R., Bartelmann, M., Bartlett, J. G., Bartolo, N., Basak, S., Battaner, E., Battye, R., Benabed, K., Benoît, A., Benoit-Lévy, A., Bernard, J. -P., Bersanelli, M., Bertincourt, B., Bethermin, M., Bielewicz, P., Bikmaev, I., Blanchard, A., Bobin, J., Bock, J. J., Böhringer, H., Bonaldi, A., Bonavera, L., Bond, J. R., Borrill, J., Bouchet, F. R., Boulanger, F., Bourdin, H., Bowyer, J. W., Bridges, M., Brown, M. L., Bucher, M., Burenin, R., Burigana, C., Butler, R. C., Calabrese, E., Cappellini, B., Cardoso, J. -F., Carr, R., Carvalho, P., Casale, M., Castex, G., Catalano, A., Challinor, A., Chamballu, A., Chary, R. -R., Chen, X., Chiang, H. C., Chiang, L. -Y, Chon, G., Christensen, P. R., Churazov, E., Church, S., Clemens, M., Clements, D. L., Colombi, S., Colombo, L. P. L., Combet, C., Comis, B., Couchot, F., Coulais, A., Crill, B. P., Cruz, M., Curto, A., Cuttaia, F., Da Silva, A., Dahle, H., Danese, L., Davies, R. D., Davis, R. J., de Bernardis, P., de Rosa, A., de Zotti, G., Déchelette, T., Delabrouille, J., Delouis, J. -M., Démoclès, J., Désert, F. -X., Dick, J., Dickinson, C., Diego, J. M., Dolag, K., Dole, H., Donzelli, S., Doré, O., Douspis, M., Ducout, A., Dunkley, J., Dupac, X., Efstathiou, G., Elsner, F., Enßlin, T. A., Eriksen, H. K., Fabre, O., Falgarone, E., Falvella, M. C., Fantaye, Y., Fergusson, J., Filliard, C., Finelli, F., Flores-Cacho, I., Foley, S., Forni, O., Fosalba, P., Frailis, M., Fraisse, A. A., Franceschi, E., Freschi, M., Fromenteau, S., Frommert, M., Gaier, T. C., Galeotta, S., Gallegos, J., Galli, S., Gandolfo, B., Ganga, K., Gauthier, C., Génova-Santos, R. T., Ghosh, T., Giard, M., Giardino, G., Gilfanov, M., Girard, D., Giraud-Héraud, Y., Gjerløw, E., González-Nuevo, J., Górski, K. M., Gratton, S., Gregorio, A., Gruppuso, A., Gudmundsson, J. E., Haissinski, J., Hamann, J., Hansen, F. K., Hansen, M., Hanson, D., Harrison, D. L., Heavens, A., Helou, G., Hempel, A., Henrot-Versillé, S., Hernández-Monteagudo, C., Herranz, D., Hildebrandt, S. R., Hivon, E., Ho, S., Hobson, M., Holmes, W. A., Hornstrup, A., Hou, Z., Hovest, W., Huey, G., Huffenberger, K. M., Hurier, G., Ilić, S., Jaffe, A. H., Jaffe, T. R., Jasche, J., Jewell, J., Jones, W. C., Juvela, M., Kalberla, P., Kangaslahti, P., Keihänen, E., Kerp, J., Keskitalo, R., Khamitov, I., Kiiveri, K., Kim, J., Kisner, T. S., Kneissl, R., Knoche, J., Knox, L., Kunz, M., Kurki-Suonio, H., Lacasa, F., Lagache, G., Lähteenmäki, A., Lamarre, J. -M., Langer, M., Lasenby, A., Lattanzi, M., Laureijs, R. J., Lavabre, A., Lawrence, C. R., Jeune, M. Le, Leach, S., Leahy, J. P., Leonardi, R., León-Tavares, J., Leroy, C., Lesgourgues, J., Lewis, A., Li, C., Liddle, A., Liguori, M., Lilje, P. B., Linden-Vørnle, M., Lindholm, V., López-Caniego, M., Lowe, S., Lubin, P. M., Macías-Pérez, J. F., MacTavish, C. J., Maffei, B., Maggio, G., Maino, D., Mandolesi, N., Mangilli, A., Marcos-Caballero, A., Marinucci, D., Maris, M., Marleau, F., Marshall, D. J., Martin, P. G., Martínez-González, E., Masi, S., Massardi, M., Matarrese, S., Matsumura, T., Matthai, F., Maurin, L., Mazzotta, P., McDonald, A., McEwen, J. D., McGehee, P., Mei, S., Meinhold, P. R., Melchiorri, A., Melin, J. -B., Mendes, L., Menegoni, E., Mennella, A., Migliaccio, M., Mikkelsen, K., Millea, M., Miniscalco, R., Mitra, S., Miville-Deschênes, M. -A., Molinari, D., Moneti, A., Montier, L., Morgante, G., Morisset, N., Mortlock, D., Moss, A., Munshi, D., Murphy, J. A., Naselsky, P., Nati, F., Natoli, P., Negrello, M., Nesvadba, N. P. H., Netterfield, C. B., Nørgaard-Nielsen, H. U., North, C., Noviello, F., Novikov, D., Novikov, I., O'Dwyer, I. J., Orieux, F., Osborne, S., O'Sullivan, C., Oxborrow, C. A., Paci, F., Pagano, L., Pajot, F., Paladini, R., Pandolfi, S., Paoletti, D., Partridge, B., Pasian, F., Patanchon, G., Paykari, P., Pearson, D., Pearson, T. J., Peel, M., Peiris, H. V., Perdereau, O., Perotto, L., Perrotta, F., Pettorino, V., Piacentini, F., Piat, M., Pierpaoli, E., Pietrobon, D., Plaszczynski, S., Platania, P., Pogosyan, D., Pointecouteau, E., Polenta, G., Ponthieu, N., Popa, L., Poutanen, T., Pratt, G. W., Prézeau, G., Prunet, S., Puget, J. -L., Pullen, A. R., Rachen, J. P., Racine, B., Rahlin, A., Räth, C., Reach, W. T., Rebolo, R., Reinecke, M., Remazeilles, M., Renault, C., Renzi, A., Riazuelo, A., Ricciardi, S., Riller, T., Ringeval, C., Ristorcelli, I., Robbers, G., Rocha, G., Roman, M., Rosset, C., Rossetti, M., Roudier, G., Rowan-Robinson, M., Rubiño-Martín, J. A., Ruiz-Granados, B., Rusholme, B., Salerno, E., Sandri, M., Sanselme, L., Santos, D., Savelainen, M., Savini, G., Schaefer, B. M., Schiavon, F., Scott, D., Seiffert, M. D., Serra, P., Shellard, E. P. S., Smith, K., Smoot, G. F., Souradeep, T., Spencer, L. D., Starck, J. -L., Stolyarov, V., Stompor, R., Sudiwala, R., Sunyaev, R., Sureau, F., Sutter, P., Sutton, D., Suur-Uski, A. -S., Sygnet, J. -F., Tauber, J. A., Tavagnacco, D., Taylor, D., Terenzi, L., Texier, D., Toffolatti, L., Tomasi, M., Torre, J. -P., Tristram, M., Tucci, M., Tuovinen, J., Türler, M., Tuttlebee, M., Umana, G., Valenziano, L., Valiviita, J., Van Tent, B., Varis, J., Vibert, L., Viel, M., Vielva, P., Villa, F., Vittorio, N., Wade, L. A., Wandelt, B. D., Watson, C., Watson, R., Wehus, I. K., Welikala, N., Weller, J., White, M., White, S. D. M., Wilkinson, A., Winkel, B., Xia, J. -Q., Yvon, D., Zacchei, A., Zibin, J. P., and Zonca, A.
Subjects: Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract: The ESA's Planck satellite, dedicated to studying the early Universe and its subsequent evolution, was launched 14 May 2009 and has been scanning the microwave and submillimetre sky continuously since 12 August 2009. This paper gives an overview of the mission and its performance, the processing, analysis, and characteristics of the data, the scientific results, and the science data products and papers in the release. The science products include maps of the CMB and diffuse extragalactic foregrounds, a catalogue of compact Galactic and extragalactic sources, and a list of sources detected through the SZ effect. The likelihood code used to assess cosmological models against the Planck data and a lensing likelihood are described. Scientific results include robust support for the standard six-parameter LCDM model of cosmology and improved measurements of its parameters, including a highly significant deviation from scale invariance of the primordial power spectrum. The Planck values for these parameters and others derived from them are significantly different from those previously determined. Several large-scale anomalies in the temperature distribution of the CMB, first detected by WMAP, are confirmed with higher confidence. Planck sets new limits on the number and mass of neutrinos, and has measured gravitational lensing of CMB anisotropies at greater than 25 sigma. Planck finds no evidence for non-Gaussianity in the CMB. Planck's results agree well with results from the measurements of baryon acoustic oscillations. Planck finds a lower Hubble constant than found in some more local measures. Some tension is also present between the amplitude of matter fluctuations derived from CMB data and that derived from SZ data. The Planck and WMAP power spectra are offset from each other by an average level of about 2% around the first acoustic peak.
Published: 2013
Full Text: View/download PDF

6. An optimal estimator for the CMB-LSS angular power spectrum and its application to WMAP and NVSS data

Author: Schiavon, F., Finelli, F., Gruppuso, A., Marcos-Caballero, A., Vielva, P., Crittenden, R. G., Barreiro, R. B., and Martinez-Gonzalez, E.
Subjects: Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract: We use a Quadratic Maximum Likelihood (QML) method to estimate the angular power spectrum of the cross-correlation between cosmic microwave background and large scale structure maps as well as their individual auto-spectra. We describe our implementation of this method and demonstrate its accuracy on simulated maps. We apply this optimal estimator to WMAP 7-year and NRAO VLA Sky Survey (NVSS) data and explore the robustness of the angular power spectrum estimates obtained by the QML method. With the correction of the declination systematics in NVSS, we can safely use most of the information contained in this survey. We then make use of the angular power spectrum estimates obtained by the QML method to derive constraints on the dark energy critical density in a flat $\Lambda$CDM model by different likelihood prescriptions. When using just the cross-correlation between WMAP 7 year and NVSS maps with 1.8$^\circ$ resolution, the best-fit model has a cosmological constant of approximatively 70% of the total energy density, disfavouring an Einstein-de Sitter Universe at more than 2 $\sigma$ CL (confidence level)., Comment: 12 pages, 12 figures
Published: 2012
Full Text: View/download PDF

7. AB0771 FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE

Author: Treppo, E., primary, Isola, M., additional, De Martino, M., additional, Padoan, R., additional, Urban, M. L., additional, Monti, S., additional, Sartorelli, S., additional, Giollo, A., additional, Argolini, L. M., additional, Marvisi, C., additional, Gattamelata, A., additional, Regola, F., additional, Ferro, F., additional, Cassone, G., additional, Motta, F., additional, Berti, A., additional, Conticini, E., additional, Guiducci, S., additional, Matucci-Cerinic, M., additional, Lo Gullo, A., additional, Manfredi, A., additional, Frediani, B., additional, Bortolotti, R., additional, Selmi, C., additional, Baldini, C., additional, Franceschini, F., additional, Conti, F., additional, Emmi, G., additional, Caporali, R., additional, Rossini, M., additional, Dagna, L., additional, Montecucco, C., additional, Schiavon, F., additional, Salvarani, C., additional, De Vita, S., additional, and Quartuccio, L., additional
Published: 2023
Full Text: View/download PDF

8. AB0789 AVACOPAN IN THE REAL-LIFE PRACTICE: EVALUATION OF EFFICACY, SAFETY, AND IMPACT ON QUALITY OF LIFE IN THE EARLY STAGES OF TREATMENT

Author: Treppo, E., primary, Bello, F., additional, Galli, E., additional, Padoan, R., additional, Monti, S., additional, Moroni, L., additional, Tombetti, E., additional, Affatato, S., additional, Conticini, E., additional, Frediani, B., additional, Alberici, F., additional, Dagna, L., additional, Montecucco, C., additional, Schiavon, F., additional, Emmi, G., additional, Salvarani, C., additional, and Quartuccio, L., additional
Published: 2023
Full Text: View/download PDF

9. POS1176 HOSPITALIZATION RATES, FEATURES, AND DISCHARGE DIAGNOSES OF A LARGE NATIONWIDE COHORT OF ANCA-ASSOCIATED VASCULITIS

Author: Berti, A., primary, Ottone, M., additional, Sartorelli, S., additional, Treppo, E., additional, Bettiol, A., additional, Padoan, R., additional, Regola, F., additional, Monti, S., additional, Marvisi, C., additional, Giollo, A., additional, Argolini, L. M., additional, Righini, M., additional, Gattamelata, A., additional, Cassone, G., additional, Sottini, L., additional, Maule, M., additional, Toniati, P., additional, Palermo, B. L., additional, Bello, F., additional, Guella, S., additional, Izzo, R., additional, Muratore, F., additional, Catanoso, M. G., additional, Fassio, A., additional, Cataleta, P., additional, Buscaroli, A., additional, Giorgi Rossi, P., additional, Franceschini, F., additional, Caporali, R., additional, Montecucco, C., additional, Conti, F., additional, Emmi, G., additional, Quartuccio, L., additional, Paolazzi, G., additional, Dagna, L., additional, Schiavon, F., additional, Salvarani, C., additional, and Bortolotti, R., additional
Published: 2023
Full Text: View/download PDF

10. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Author: Bettiol, A., Urban, M. L., Dagna, L., Cottin, V., Franceschini, F., Del Giacco, S., Schiavon, F., Neumann, T., Lopalco, G., Novikov, P., Baldini, C., Lombardi, C., Berti, A., Alberici, F., Folci, M., Negrini, S., Sinico, R. A., Quartuccio, L., Lunardi, C., Parronchi, P., Moosig, F., Espigol-Frigole, G., Schroeder, J., Kernder, A. L., Monti, S., Silvagni, E., Crimi, C., Cinetto, F., Fraticelli, P., Roccatello, D., Vacca, A., Mohammad, A. J., Hellmich, B., Samson, M., Bargagli, E., Cohen Tervaert, J. W., Ribi, C., Fiori, D., Bello, F., Fagni, F., Moroni, L., Ramirez, G. A., Nasser, M., Marvisi, C., Toniati, P., Firinu, D., Padoan, R., Egan, A., Seeliger, B., Iannone, F., Salvarani, C., Jayne, D., Prisco, D., Vaglio, A., Emmi, G., Ahmad, K., Beccalli, M., Bonnotte, B., Bortolotti, R., Cariddi, A., Caminati, M., Cid, M. C., Deidda, M., Delvino, P., Scala, G. D., Felicetti, M., Ferro, F., Furini, F., Gelain, E., Ghirelli, G., Holle, J., Losappio, L. M., Mahr, A., Malandrino, D., Marhhold, J., Mattioli, I., Moi, L., Moiseev, S., Muratore, F., Nolasco, S., Olivieri, B., Palermo, A., Regola, F., Sander, O., Scarpa, R., Sciascia, S., Silvestri, E., Susca, N., Terrier, B., Treppo, E., Trezzi, B., Uzzo, M., Vitiello, G., Yacyshyn, E., RS: MHeNs - R3 - Neuroscience, Faculteit FHML Centraal, Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Jayne, David [0000-0002-1712-0637], and Apollo - University of Cambridge Repository
Subjects: Male, Epidemiology, Birmingham Vasculitis Activity Score, law.invention, Glucocorticoid, Randomized controlled trial, Prednisone, law, Eosinophilic, Monoclonal, Immunology and Allergy, Humanized, PLACEBO, Middle Aged, egpa mepolizumab, Treatment Outcome, SAFETY, Female, ANCA-associated Vasculitis, Biologicals, Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss), Glucocorticoids, Granulomatosis with polyangiitis, ANCA-associated Vasculiti, medicine.drug, Keywords: ANCA-associated Vasculitis, Adult, medicine.medical_specialty, Immunology, Antibodies, Monoclonal, Humanized, Antibodies, Drug Administration Schedule, Eosinophilia, Granulomatosis with Polyangiitis, Humans, Retrospective Studies, Rheumatology, Internal medicine, medicine, Adverse effect, Asthma, business.industry, medicine.disease, Biological, EGPA, European EGPA Study Group, business, FOLLOW-UP, Mepolizumab
Abstract: OBJECTIVE: Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real-life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort. METHODS: We included all patients with EGPA treated with mepolizumab at the recruiting centers in 2015-2020. Treatment response was evaluated from 3 months to 24 months after initiation of mepolizumab. Complete response to treatment was defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a prednisolone or prednisone dose (or equivalent) of ��4 mg/day. Respiratory outcomes included asthma and ear, nose, and throat (ENT) exacerbations. RESULTS: Two hundred three patients, of whom 191 received a stable dose of mepolizumab (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were included. Twenty-five patients (12.3%) had a complete response to treatment at 3 months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 months, respectively, and rates were comparable between mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, with no significant differences observed between 100 mg every 4 weeks and 300 mg every 4 weeks. Eighty-two patients (40.4%) experienced asthma exacerbations (57 of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events (AEs), most of which were nonserious AEs (38 of 44). CONCLUSION: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial.
Published: 2022
Full Text: View/download PDF

11. Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis

Author: Monti, S, Felicetti, M, Delvino, P, Padoan, R, Berti, A, Paolazzi, G, Brunori, G, Schiavon, F, Caporali, R, Montecucco, C, Monti S., Felicetti M., Delvino P., Padoan R., Berti A., Paolazzi G., Brunori G., Schiavon F., Caporali R., Montecucco C., Monti, S, Felicetti, M, Delvino, P, Padoan, R, Berti, A, Paolazzi, G, Brunori, G, Schiavon, F, Caporali, R, Montecucco, C, Monti S., Felicetti M., Delvino P., Padoan R., Berti A., Paolazzi G., Brunori G., Schiavon F., Caporali R., and Montecucco C.
Abstract: Objective. It has been suggested that anti-neutrophil cytoplasmic antibody (ANCA) specificity, rather than clinical diagnosis influences the phenotype and course of ANCA-associated vasculitis (AAV). However, preliminary evidence suggests that further combined levels of categorisation might be of clinical relevance. The aim of this study was to investigate differences in clinical presentation at disease onset and outcomes based on clinical diagnosis and ANCA specificity. Methods. Newly diagnosed patients with GPA or MPA assessed in three referral centres between 2000 and 2016 were included. Patients were grouped as MPO-ANCA-positive granulomatosis with polyangiitis (MPO-GPA), PR3-ANCA-positive-GPA (PR3-GPA), and MPO-ANCA-positive microscopic polyangiitis (MPO-MPA). Results. Of the 143 AAV patients included (female 52%), 87 were categorised as PR3-GPA, 23 as MPO-GPA, and 33 as MPO-MPA. Patients with MPO-GPA were significantly younger than MPA patients (age 49±15 versus 63±10; p<0.001). MPO-GPA had significantly more frequent subglottic stenosis compared to PR3-GPA. Ear, nose, throat involvement was significantly more frequent in both GPA groups compared to MPA. Type of pulmonary involvement differed between both GPA groups and MPA with diffuse pulmonary haemorrhage being significantly more frequent in the latter (7% in PR3-GPA, 0% in MPO-GPA, 27% in MPO-MPA; p<0.001). Renal involvement was more frequent in MPO-MPA compared to both MPO-GPA and PR3-GPA (impaired renal function in 84%, 39%, and 36%, respectively; p<0.001). PR3-GPA relapsed significantly more than the other two groups. After adjusting for age, MPO-GPA was a significant risk factor for mortality [HR 4.44 (95%CI 1.46-13.52), p=0.009]. Conclusion. ANCA specificity identifies specific subsets of disease characterised by different clinical presentation and outcome within the clinical diagnosis of GPA.
Published: 2021

12. Prédiction de l’évolution à long terme de la granulomatose éosinophilique avec polyangéite à partir d’une cohorte rétrospective européenne de 809 patients

Author: Papo, M, Martinot, P, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Jayne, D, Hellmich, B, Kahn, J, Durel, C, Emmi, G, Vaglio, A, Porcher, R, Terrier, B, Papo, M., Martinot, P., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Jayne, D., Hellmich, B., Kahn, J. E., Durel, C. A., Emmi, G., Vaglio, A., Porcher, R., Terrier, B., Papo, M, Martinot, P, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Jayne, D, Hellmich, B, Kahn, J, Durel, C, Emmi, G, Vaglio, A, Porcher, R, Terrier, B, Papo, M., Martinot, P., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Jayne, D., Hellmich, B., Kahn, J. E., Durel, C. A., Emmi, G., Vaglio, A., Porcher, R., and Terrier, B.
Published: 2021

13. Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis

Author: Monti, S., Felicetti, M., Paolo Delvino, Padoan, R., Berti, A., Paolazzi, G., Brunori, G., Schiavon, F., Caporali, R., and Montecucco, C.
Subjects: Adult, Myeloblastin, Immunology, Antineutrophil Cytoplasmic, Granulomatosis with Polyangiitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Middle Aged, Antibodies, Antibodies, Antineutrophil Cytoplasmic, Rheumatology, Humans, Immunology and Allergy, Female, Peroxidase, Retrospective Studies
Abstract: It has been suggested that anti-neutrophil cytoplasmic antibody (ANCA) specificity, rather than clinical diagnosis influences the phenotype and course of ANCA-associated vasculitis (AAV). However, preliminary evidence suggests that further combined levels of categorisation might be of clinical relevance. The aim of this study was to investigate differences in clinical presentation at disease onset and outcomes based on clinical diagnosis and ANCA specificity.Newly diagnosed patients with GPA or MPA assessed in three referral centres between 2000 and 2016 were included. Patients were grouped as MPO-ANCA-positive granulomatosis with polyangiitis (MPO-GPA), PR3-ANCA-positive-GPA (PR3-GPA), and MPO-ANCA-positive microscopic polyangiitis (MPO-MPA).Of the 143 AAV patients included (female 52%), 87 were categorised as PR3-GPA, 23 as MPO-GPA, and 33 as MPO-MPA. Patients with MPO-GPA were significantly younger than MPA patients (age 49±15 versus 63±10; p0.001). MPO-GPA had significantly more frequent subglottic stenosis compared to PR3-GPA. Ear, nose, throat involvement was significantly more frequent in both GPA groups compared to MPA. Type of pulmonary involvement differed between both GPA groups and MPA with diffuse pulmonary haemorrhage being significantly more frequent in the latter (7% in PR3-GPA, 0% in MPO-GPA, 27% in MPOMPA; p0.001). Renal involvement was more frequent in MPO-MPA compared to both MPO-GPA and PR3-GPA (impaired renal function in 84%, 39%, and 36%, respectively; p0.001). PR3-GPA relapsed significantly more than the other two groups. After adjusting for age, MPO-GPA was a significant risk factor for mortality [HR 4.44 (95%CI 1.46-13.52), p=0.009].ANCA specificity identifies specific subsets of disease characterised by different clinical presentation and outcome within the clinical diagnosis of GPA.
Published: 2021

14. Séquelles à long terme au cours de la granulomatose éosinophilique avec polyangéite : données issues d’une étude rétrospective multicentrique de 845 patients

Author: Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Durel, C, Vaglio, A, Emmi, G, Guillevin, L, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Jayne, D., Hellmich, B., Salvarani, C., Kahn, J. E., Durel, C. A., Vaglio, A., Emmi, G., Guillevin, L., Terrier, B., Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Durel, C, Vaglio, A, Emmi, G, Guillevin, L, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Jayne, D., Hellmich, B., Salvarani, C., Kahn, J. E., Durel, C. A., Vaglio, A., Emmi, G., Guillevin, L., and Terrier, B.
Published: 2020

15. Émulation d’un essai clinique comparant les corticoïdes versus les corticoïdes plus le cyclophosphamide au cours de la granulomatose éosinophilique avec polyangéite sévère

Author: Sorin, B., Papo, M., Sinico, R.A., Teixeira, V., Venhoff, N., Urban, M.L., Mahrhold, J., Locatelli, F., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Groh, M., Marvisi, C., Samson, M., Barba, T., Jayne, D., Troilo, A., Thiel, J., Hellmich, B., Monti, S., Montecucco, C., Salvarani, C., Kahn, J.E., Durel, C.A., Mouthon, L., Guillevin, L., Giacomo, E., Vaglio, A., Porcher, R., and Terrier, B.
Published: 2024
Full Text: View/download PDF

16. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes

Author: Monti, S., Craven, A., Klersy, C., Montecucco, C., Caporali, R., Watts, R., Merkel, P. A., Luqmani, R., Achilleos, K., Adler, M., Alba, M. A., Albert, D. A., Alibaz-Oner, F., Allcoat, P., Amano, K., Amarasuriya, M., Amudala, N. A., Andrews, J., Archer, A. M., Arimura, Y., Atukorala, I., Azevedo, E., Bajad, S., Baldwin, C., Barra, L. J., Baslund, B., Basu, N., Baykal, M., Berger, C., Berglin, E., Besada, E., Bhardwaj, M., Bischof, A., Blockmans, D., Blood, J., Draibe, J. B., Brand, S., Brandao, M., Bruce, I. N., Butler, A., Calabrese, L. H., Ferrer, D. C., Carette, S., Carmona, D., Ceunen, H., Chakravarty, K., Chapman, P. T., Chocova, Z., Chung, S. A., Ci, W., Cid, M. C., Clark, T. M., Clarkson, M. R., De Jesus Contreras-Rodriguez, F., Conway, R., Cooke, K., Viros, X. C., Cordeiro, A., Costa, A., Culfear, K., Daikeler, T., Danda, D., Das, S. K., Dasgupta, B., De Castro, A. M., Dehghan, N., Devassy, R., Dhindsa, N., Diamantopoulos, A. P., Direskeneli, H., Dobashi, H., Juan, D., Durrani, M., Edelsten, C., Eifert, J., Elhayek, S., Elsideeg, S., Endo, T., Erden, A., Erer, B., Eriksson, P., Erturk, Z., Espigol-Frigole, G., Felicetti, M., Ferraro, A., Ferro, J. M., Fifi-Mah, A., Flores-Suarez, L. F., Flossmann, O., Flynn, D., Fonseca, J. E., Foot, J., Foote, M., Forbess, L., Fujimoto, S., Fukuoka, K., Furtado, C., Furuta, S., Gaffo, A. L., Gallagher, P., Gao, N., Gatenby, P., Gendi, N., Geraldes, R., Gerits, A., Gioffredi, A., Gomples, L., Goncalves, M. J., Gondo, P., Graham, A., Grainger, R., Gray, D. T., Grayson, P. C., Griffiths, L., Guo, Y., Gupta, R., Gylling, M., Hajj-Ali, R. A., Hammam, N., Harigai, M., Hartley, L., Haslett, J., Hassan, A., Hatemi, G., Hellmich, B., Henckaerts, L., Henes, J. C., Hepburn, J., Herd, V., Hess, C., Hill, C., Hinojosa-Azaola, A., Hirahashi, J., Hirano, F., Hocevar, A., Holle, J., Hollinger, N., Homma, S., Howard, T., Hoyles, R. K., Hruskova, Z., Hutcheon, G., Ignacak, M., Igney-Oertel, A., Ikeda, K., Ikegaya, N., Jagadeesh, S., Jaquith, J., Jayne, D. R. W., Jewell, T., Jones, C., Joshi, A., Kalyoncu, U., Kamall, S., Kamath, S., Lai, K. S., Kaname, S., Kanchinadham, S., Karadag, O., Karube, M., Kaszuba, M., Kaur, R., Kawakami, T., Kawashima, S., Khalidi, N., Khan, A., Kikuchi, M., Kilic, L., Kimura, M., King, M. J., Klapa, S., Klocke, R., Kobayashi, T., Kobayashi, S., Komagata, Y., Kronbichler, A., Kuczia, P., Kumar, M. S., Kurosawa, M., Lamprecht, P., Langford, C. A., Lanyon, P., Laversuch, C., Lee, S. J., Leoni, S., Li, J., Liang, K., Liang, P., Liao, H., Lee, L. A., Luqmani, R. A., Lyle, A., Macdonald, M., Mackie, S. L., Madden, L., Magliano, M., Makino, H., Makol, A., Malaiya, R., Malaviya, A., Manthri, R., Maritati, F., Da Silva, A. M., Mason, J. C., Matara, C., Matsui, K., Matteson, E. L., Mcbride, D., Mccullough, K., Mcgeoch, L., Mclaren, J., Mcmillian, C., Mendiratta, N., Menon, A., Merinopoulos, D., Merkel, P., Messier, S., Micheletti, R. G., Mills, K., Milman, N., Minoda, M., Minz, R. W., Mock, C., Mohammad, A. J., Moiseev, S., Moitinho, M., Molloy, E., Monach, P. A., Montgomery, M., Moosig, F., Moradizadeh, M., Morgan, M., Morgan, A. W., Morgan, A. -M., Muir, A., Mukhtyar, C., Muller, A., Muratore, F., Muso, E., Nada, R., Nakajima, H., Nakajima, T., Nakano, H., Nandagudi, A., Neumann, T., Y. F., Ng, K. H., Ng, Nogueira, E. L., Nolkha, N., Nordstrom, D., Novikov, P., Nugaliyadde, A., O'Donnell, J. L., O'Donoghue, J., O'Neill, L., O'Riordan, E., Oatley, M., Okubo, K., Oliva, E., Oshikawa, H., Ota, Y., Padoan, R., Pagnoux, C., Pan, L., Panaritis, K., Park, J. K., Patel, S., Patil, P., Pazzola, G., Peall, A., Pearce, F., Pehlevan, S., Pereira, L., Pettersson, T., Pineau, C. A., Pirila, L., Poglodek, B., Ponte, C., Prieto-Gonzalez, S., Priya, S. R., Purewal, B., Purschke, S., Putaala, J., Quickert, S., Quincey, V., Raghuvanshi, S., Rajasekhar, L., Ranganathan, D., Rathi, M., Rees, D., Rees, F., Renken, U., Restuccia, G., Rhee, R. L., Rice, B., Robins, D., Robson, J., Rodrigues, M., Romao, V. C., Rotar, C., Ruediger, C., Rutgers, A., A. C., Sa, Saavedra, M. J., Sada, K. -E., Sahbudin, I., Salvarani, C., Sandhu, N., Santos, E., Sato, Y., Schafer, V. S., Schiavon, F., Schmidt, W. A., Segelmark, M., Shahin, A., Sharma, A., Shotton, J., Silva, C., Singer, O. G., Sivasuthan, G., Smolen, S., Solanich-Moreno, X., Boixader, L. S., Song, Y. W., Springer, J., Sreih, A. G., Srivastava, R., Stamp, L. K., Stevens, R., Strbian, D., Sugino, K., Sunderkotter, C., Suppiah, R., Suzuki, K., Szekanecz, Z., Sznajd, J., Taimen, K., Tak, P. P., Takeuchi, T., Takizawa, N., Tames, L., Tan, B. E., Tanaka, M., Tang, M. W., Tatlisumak, T., Tesar, V., Thomas, A., Tian, X., Tokunaga, K., Tombetti, E., Tomsic, M., Toz, B., Tsukamoto, T., Uchida, S., Unal, A. U., Urban, M. L., Usui, J., Vaglio, A., Venkatachalam, S., Vermaak, E., Viswanath, V., Wada, T., Wagh, S., Wallace, D. J., Walters, G., Walz, B., Wan, J., Wang, T., Wang, G., Warrington, K. J., Watts, R. A., Wawrzycka-Adamczyk, K., Weeratunga, P., Weisman, M. H., Wickramasinghe, S., Williams, M., Wojcik, K., Woodruff, L., Xenitidis, T., Yamada, H., Yamagata, K., Yee, C. -S., Yoon, M., Yoshida, K., Yoshifuji, H., Ytterberg, S. R., Yumura, W., Zayed, H., Zeng, X., Zhao, M. -H., Zugaj, A., Zuk, J., İç Hastalıkları, Clinical Haematology, and Translational Immunology Groningen (TRIGR)
Subjects: Male, Outcome, Antineutrophil Cytoplasmic, 030232 urology & nephrology, 0302 clinical medicine, Risk Factors, 80 and over, Pharmacology (medical), Age of Onset, Young adult, Aged, 80 and over, education.field_of_study, age, anti-neutrophil cytoplasmic antibody-associated vasculitis, outcome, Adolescent, Adult, Aged, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antibodies, Antineutrophil Cytoplasmic, Female, Humans, Middle Aged, Morbidity, Prognosis, Retrospective Studies, Risk Assessment, Survival Rate, United Kingdom, Young Adult, Vasculitis, Systemic vasculitis, medicine.medical_specialty, Population, anti-neutrophil cytoplasmic antibody–associated vasculitis, Antibodies, 03 medical and health sciences, Rheumatology, Internal medicine, medicine, education, Anti-neutrophil cytoplasmic antibody–associated vasculitis, Survival rate, Anti-neutrophil cytoplasmic antibody, 030203 arthritis & rheumatology, business.industry, Retrospective cohort study, medicine.disease, Age of onset, business
Abstract: Objectives ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- and older-onset patients are still incompletely understood. Methods We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: Results A total of 1338 patients with AAV were included: 66% had disease onset at Conclusion Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients.
Published: 2021

17. Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

Author: Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Urban, Maria Letizia, Dagna, Lorenzo, Cottin, Vincent, Franceschini, Franco, Del Giacco, Stefano, Schiavon, Franco, Neumann, Thomas, Lopalco, Giuseppe, Novikov, Pavel, Baldini, Chiara, Lombardi, Carlo, Berti, Alvise, Alberici, Federico, Folci, Marco, Negrini, Simone, Sinico, Renato Alberto, Quartuccio, Luca, Lunardi, Claudio, Parronchi, Paola, Moosig, Frank, Espígol-Frigolé, Georgina, Schroeder, Jan, Kernder, Anna Luise, Monti, Sara, Silvagni, Ettore, Crimi, Claudia, Cinetto, Francesco, Fraticelli, Paolo, Roccatello, Dario, Vacca, Angelo, Mohammad, Aladdin J, Hellmich, Bernhard, Samson, Maxime, Bargagli, Elena, Cohen Tervaert, Jan Willem, Ribi, Camillo, Fiori, Davide, Bello, Federica, Fagni, Filippo, Moroni, Luca, Ramirez, Giuseppe Alvise, Nasser, Mouhamad, Marvisi, Chiara, Toniati, Paola, Firinu, Davide, Padoan, Roberto, Egan, Allyson, Seeliger, Benjamin, Iannone, Florenzo, Salvarani, Carlo, Jayne, David, Prisco, Domenico, Vaglio, Augusto, Emmi, Giacomo, Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Urban, Maria Letizia, Dagna, Lorenzo, Cottin, Vincent, Franceschini, Franco, Del Giacco, Stefano, Schiavon, Franco, Neumann, Thomas, Lopalco, Giuseppe, Novikov, Pavel, Baldini, Chiara, Lombardi, Carlo, Berti, Alvise, Alberici, Federico, Folci, Marco, Negrini, Simone, Sinico, Renato Alberto, Quartuccio, Luca, Lunardi, Claudio, Parronchi, Paola, Moosig, Frank, Espígol-Frigolé, Georgina, Schroeder, Jan, Kernder, Anna Luise, Monti, Sara, Silvagni, Ettore, Crimi, Claudia, Cinetto, Francesco, Fraticelli, Paolo, Roccatello, Dario, Vacca, Angelo, Mohammad, Aladdin J, Hellmich, Bernhard, Samson, Maxime, Bargagli, Elena, Cohen Tervaert, Jan Willem, Ribi, Camillo, Fiori, Davide, Bello, Federica, Fagni, Filippo, Moroni, Luca, Ramirez, Giuseppe Alvise, Nasser, Mouhamad, Marvisi, Chiara, Toniati, Paola, Firinu, Davide, Padoan, Roberto, Egan, Allyson, Seeliger, Benjamin, Iannone, Florenzo, Salvarani, Carlo, Jayne, David, Prisco, Domenico, Vaglio, Augusto, and Emmi, Giacomo
Abstract: Objective: Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort. Methods: We included all EGPA patients treated with mepolizumab at the recruiting centres in 2015-2020. Treatment response was evaluated from month 3 through 24 (T3-T24) after mepolizumab starting. Complete response (CR) was defined as no disease activity (Birmingham Vasculitis Activity Score, BVAS=0) and a prednisone dose ≤4mg/day. Respiratory outcomes included asthma and ear-nose-throat (ENT) exacerbations. Results: We included 203 patients, of whom 191 at stable dosage (158 mepolizumab 100mg/4 weeks, 33 300mg/4 weeks). At T3, 25 patients (12.3%) had a CR. CR rates increased to 30.4% and 35.7% at T12 and T24 and were comparable between mepolizumab 100 and 300mg/4 weeks. Mepolizumab led to a significant reduction in BVAS, prednisone dose, eosinophil counts from T3 through T24, with no significant differences between 100 and 300 mg/4weeks. Eighty-two patients (40.4%) experienced asthma exacerbations [57/158 (36%) on 100mg/4 weeks; 17/33 (52%) on 300mg/4 weeks]. Thirty-one (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events, most being non-serious (38/44). Conclusion: Mepolizumab both at 100 and 300mg/4 weeks is effective for EGPA. The two dosages should be compared in the setting of a controlled trial.
Published: 2022

18. POS0838 INCIDENCE OF CANCER IS SIGNIFICANTLY INCREASED IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PATIENTS: RESULTS FROM A MULTICENTRE STUDY.

Author: Padoan, R., primary, Zorzi, M., additional, Battagello, J., additional, Zagonel, V., additional, Emmi, G., additional, Baldini, C., additional, Monti, S., additional, Quartuccio, L., additional, Doria, A., additional, and Schiavon, F., additional
Published: 2022
Full Text: View/download PDF

19. POS0813 GLUCOCORTICOIDS, CONVENTIONAL DMARDs AND TOCILIZUMAB DIFFERENTLY AFFECT 18F-FDG PET METABOLIC ACTIVITY IN GIANT CELL ARTERITIS PATIENTS.

Author: Iorio, L., primary, Campaniello, D., additional, Zucchetta, P., additional, Cecchin, D., additional, Doria, A., additional, Schiavon, F., additional, and Padoan, R., additional
Published: 2022
Full Text: View/download PDF

20. POS0837 EFFICACY OF ULTRA-LOW DOSE RITUXIMAB FOR REMISSION MAINTENANCE THERAPY IN ANCA-ASSOCIATED VASCULITIS

Author: Campaniello, D., primary, Treppo, E., additional, D’onofrio, B., additional, Franchi, G., additional, Berti, A., additional, Iorio, L., additional, Bortolotti, R., additional, Montecucco, C., additional, Monti, S., additional, Quartuccio, L., additional, Doria, A., additional, Schiavon, F., additional, and Padoan, R., additional
Published: 2022
Full Text: View/download PDF

21. AB0627 Evaluation of internal consistency, feasibility, and reliability of the Italian version of ANCA-associated vasculitis patient-reported outcome (AAV-PRO_ita) questionnaire: preliminary results from a multicenter study on a large cohort of Italian patients

Author: Treppo, E., primary, Isola, M., additional, De Martino, M., additional, Padoan, R., additional, Urban, M. L., additional, Monti, S., additional, Sartorelli, S., additional, Giollo, A., additional, Argolini, L. M., additional, Marvisi, C., additional, Ferro, F., additional, Cassone, G., additional, Motta, F., additional, Berti, A., additional, Conticini, E., additional, Manfredi, A., additional, Frediani, B., additional, Bortolotti, R., additional, Selmi, C., additional, Baldini, C., additional, Emmi, G., additional, Caporali, R., additional, Rossini, M., additional, Dagna, L., additional, Montecucco, C., additional, Schiavon, F., additional, Salvarani, C., additional, De Vita, S., additional, and Quartuccio, L., additional
Published: 2022
Full Text: View/download PDF

22. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis

Author: Grayson, P. C., Ponte, C., Suppiah, R., Robson, J. C., Craven, A., Judge, A., Khalid, S., Hutchings, A., Luqmani, R. A., Watts, R. A., Merkel, P. A., Gatenby, P., Hill, C., Ranganathan, D., Kronbichler, A., Blockmans, D., Barra, L., Carette, S., Pagnoux, C., Dhindsa, N., Fifi-Mah, A., Khalidi, N., Liang, P., Milman, N., Pineau, C., Tian, X., Wang, G., Wang, T., Zhao, M. -H., Tesar, V., Baslund, B., Hammam, N., Shahin, A., Pirila, L., Putaala, J., Hellmich, B., Henes, J., Lamprecht, P., Neumann, T., Schmidt, W., Sunderkoetter, C., Szekanecz, Z., Danda, D., Das, S., Gupta, R., Rajasekhar, L., Sharma, A., Wagh, S., Clarkson, M., Molloy, E., Salvarani, C., Schiavon, F., Tombetti, E., Vaglio, A., Amano, K., Arimura, Y., Dobashi, H., Fujimoto, S., Harigai, M., Hirano, F., Hirahashi, J., Honma, S., Kawakami, T., Kobayashi, S., Kono, H., Makino, H., Matsui, K., Muso, E., Suzuki, K., Ikeda, K., Takeuchi, T., Tsukamoto, T., Uchida, S., Wada, T., Yamada, H., Yamagata, K., Yumura, W., Lai, K. S., Flores-Suarez, L. F., Hinojosa, A., Rutgers, B., Tak, P. -P., Grainger, R., Quincey, V., Stamp, L., Besada, E., Diamantopoulos, A., Sznajd, J., Azevedo, E., Geraldes, R., Rodrigues, M., Santos, E., Song, Y. -W., Moiseev, S., Hocevar, A., Cid, M. C., Moreno, X. S., Atukorala, I., Berglin, E., Mohammed, A., Segelmark, M., Daikeler, T., Direskeneli, H., Hatemi, G., Kamali, S., Karadag, O., Pehlevan, S., Adler, M., Basu, N., Bruce, I., Chakravarty, K., Dasgupta, B., Flossmann, O., Gendi, N., Hassan, A., Hoyles, R., Jayne, D., Jones, C., Klocke, R., Lanyon, P., Laversuch, C., Luqmani, R., Robson, J., Magliano, M., Mason, J., Maw, W. W., Mcinnes, I., Mclaren, J., Morgan, M., Morgan, A., Mukhtyar, C., O'Riordan, E., Patel, S., Peall, A., Venkatachalam, S., Vermaak, E., Menon, A., Watts, R., Yee, C. -S., Albert, D., Calabrese, L., Chung, S., Forbess, L., Gaffo, A., Gewurz-Singer, O., Grayson, P., Liang, K., Matteson, E., Springer, J., Sreih, A., and Translational Immunology Groningen (TRIGR)
Subjects: Adult, Male, Vasculitis, Myeloblastin, Immunology, Churg-Strauss Syndrome, Sensitivity and Specificity, General Biochemistry, Genetics and Molecular Biology, Antibodies, Antineutrophil Cytoplasmic, Diagnosis, Differential, Rheumatology, Risk Factors, Humans, Immunology and Allergy, anti-neutrophil cytoplasm antibody, Prospective Studies, Aged, Granulomatosis with Polyangiitis, Reproducibility of Results, Middle Aged, United States, Female, eosinophilic granulomatosis with polyangiitis, Eosinophilic Granuloma, Europe, classification, Societies
Abstract: ObjectiveTo develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).MethodsPatients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate criteria items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.ResultsThe development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1×109/L (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti-proteinase 3–ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1) and haematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% CI 77% to 91%) and the specificity was 99% (95% CI 98% to 100%).ConclusionThe 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis demonstrate strong performance characteristics and are validated for use in research.
Published: 2022

23. EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS

Author: Treppo, E, Isola, M, De Martino, M, Padoan, R, Urban, Ml, Monti, S, Sartorelli, S, Giollo, A, Argolini, Lm, Marvisi, C, Ferro, F, Cassone, G, Motta, F, Berti, A, Conticini, E, Manfredi, A, Frediani, B, Bortolotti, R, Selmi, C, Baldini, C, Emmi, G, Caporali, R, Rossini, M, Dagna, L, Montecucco, C, Schiavon, F, Salvarani, C, De Vita, S, and Quartuccio, L
Published: 2022

24. Prédiction de l’évolution à long terme de la granulomatose éosinophilique avec polyangéite à partir d’une cohorte rétrospective européenne de 809 patients

Author: Papo, M., primary, Martinot, P., additional, Sinico, R.A., additional, Teixeira, V., additional, Urban, M.L., additional, Mahrhold, J., additional, Monti, S., additional, Cassone, G., additional, Schiavon, F., additional, Seeliger, B., additional, Neumann, T., additional, Kroegel, C., additional, Jayne, D., additional, Hellmich, B., additional, Kahn, J.E., additional, Durel, C.A., additional, Emmi, G., additional, Vaglio, A., additional, Porcher, R., additional, and Terrier, B., additional
Published: 2021
Full Text: View/download PDF

25. La granulomatose éosinophilique avec polyangéite (Churg-Strauss) avec positivité des ANCA-PR3 existe-t-elle réellement ?

Author: Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Samson, M, Jayne, D, Hellmich, B, Salvarani, C, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Groh, M., Samson, M., Jayne, D., Hellmich, B., Salvarani, C., Guillevin, L., Emmi, G., Vaglio, A., Terrier, B., Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Samson, M, Jayne, D, Hellmich, B, Salvarani, C, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, M., Sinico, R. A., Teixeira, V., Urban, M. L., Mahrhold, J., Monti, S., Cassone, G., Schiavon, F., Seeliger, B., Neumann, T., Kroegel, C., Groh, M., Samson, M., Jayne, D., Hellmich, B., Salvarani, C., Guillevin, L., Emmi, G., Vaglio, A., and Terrier, B.
Published: 2019

26. Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

Author: Bettiol, A., Sinico, R. A., Schiavon, F., Monti, S., Bozzolo, E. P., Franceschini, F., Govoni, M., Lunardi, C., Guida, G., Lopalco, G., Paolazzi, G., Vacca, A., Gregorini, G., Leccese, P., Piga, M., Conti, F., Fraticelli, P., Quartuccio, L., Alberici, F., Salvarani, C., Bettio, S., Negrini, S., Selmi, C., Sciascia, S., Moroni, G., Colla, L., Manno, C., Urban, M. L., Vannacci, A., Pozzi, M. R., Fabbrini, P., Polti, S., Felicetti, M., Marchi, M. R., Padoan, R., Delvino, P., Caporali, R., Montecucco, C., Dagna, L., Cariddi, A., Toniati, P., Tamanini, S., Furini, F., Bortoluzzi, A., Tinazzi, E., Delfino, L., Badiu, I., Rolla, G., Venerito, V., Iannone, F., Berti, A., Bortolotti, R., Racanelli, V., Jeannin, G., Padula, A., Cauli, A., Priori, R., Gabrielli, A., Bond, M., Tedesco, M., Pazzola, G., Tomietto, P., Pellecchio, M., Marvisi, C., Maritati, F., Palmisano, A., Dejaco, C., Willeit, J., Kiechl, S., Olivotto, I., Willeit, P., Prisco, D., Vaglio, A., Emmi, G., Bargagli, E., Becatti, M., Beccalli, M., Bello, F., Bozzao, F., Canti, V., Cassia, M. A., Cassone, G., Catanoso, M., Chieco-Bianchi, F., Clari, R., Coladonato, L., De Santis, M., Di Scala, G., Fagni, F., Fenaroli, P., Fiorillo, C., Floris, A., Fornaro, M., Galli, E., Generali, E., Giliberti, M., Lascaro, N., Leccese, I., Mattioli, I., Olivieri, B., Osti, N., Peyronel, F., Radin, M., Righetti, G., Salvati, S., Silvestri, E., Susca, N., Tamburini, C., Taurisano, G., Trezzi, B., Trivioli, G., Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, and Emmi, G
Subjects: Pulmonary and Respiratory Medicine, Burden of disease, Humans, Churg-Strauss Syndrome, Granulomatosis with Polyangiitis, Venous Thromboembolism, Venous Thrombosis, Churg-strauss syndrome, Criminology, NO, 03 medical and health sciences, 0302 clinical medicine, Medicine, 030212 general & internal medicine, Vascular inflammation, business.industry, Conflict of interest, Cytoplasmic antibody, medicine.disease, 030228 respiratory system, Wegener granulomatosis, arterial and venous thromboembolic events, Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome), Organ involvement, business, Production team
Abstract: Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss syndrome) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) characterised by respiratory manifestations and systemic organ involvement [1]. Particularly, cardiac manifestations occur in 40–60% of patients, representing the leading cause of mortality [2]. Recent reports suggest that venous thromboembolic events might also represent a consistent burden of disease [3, 4], as already known for the other AAVs [5–7], possibly due to eosinophil-mediated vascular inflammation [5]. Nevertheless, the occurrence of arterial and venous thrombotic events (AVTE) has never been systematically explored in EGPA. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Alessandra Bettiol Conflict of interest: Renato Alberto Sinico Conflict of interest: Franco Schiavon Conflict of interest: Sara Monti Conflict of interest: Enrica Paola Bozzolo Conflict of interest: Franco Franceschini Conflict of interest: Marcello Govoni Conflict of interest: Claudio Lunardi Conflict of interest: Giuseppe Guida Conflict of interest: Giuseppe Lopalco Conflict of interest: Giuseppe Paolazzi Conflict of interest: Angelo Vacca Conflict of interest: Gina Gregorini Conflict of interest: Pietro Leccese Conflict of interest: Matteo Piga Conflict of interest: Fabrizio Conti Conflict of interest: Paolo Fraticelli Conflict of interest: Luca Quartuccio Conflict of interest: Federico Alberici Conflict of interest: Carlo Salvarani Conflict of interest: Silvano Bettio Conflict of interest: Simone Negrini Conflict of interest: Carlo Selmi Conflict of interest: Savino Sciascia Conflict of interest: Gabriella Moroni Conflict of interest: Loredana Colla Conflict of interest: Carlo Manno Conflict of interest: Maria Letizia Urban Conflict of interest: Alfredo Vannacci Conflict of interest: Maria Rosa Pozzi Conflict of interest: Paolo Fabbrini Conflict of interest: Stefano Polti Conflict of interest: Mara Felicetti Conflict of interest: Maria Rita Marchi Conflict of interest: Roberto Padoan Conflict of interest: Paolo Delvino Conflict of interest: Roberto Caporali Conflict of interest: Carlomaurizio Montecucco Conflict of interest: Lorenzo Dagna Conflict of interest: Adriana Cariddi Conflict of interest: Paola Toniati Conflict of interest: Dr. Tamanini reports other from Glaxo Smith Kline, outside the submitted work. Conflict of interest: Federica Furini Conflict of interest: Alessandra Bortoluzzi Conflict of interest: Elisa Tinazzi Conflict of interest: Lorenzo Delfino Conflict of interest: Iuliana Badiu Conflict of interest: Giovanni Rolla Conflict of interest: Vincenzo Venerito Conflict of interest: Florenzo Iannone Conflict of interest: Alvise Berti Conflict of interest: Roberto Bortolotti Conflict of interest: Vito Racanelli Conflict of interest: Guido Jeannin Conflict of interest: Angela Padula Conflict of interest: Alberto Cauli Conflict of interest: Roberta Priori Conflict of interest: Armando Gabrielli Conflict of interest: Milena Bond Conflict of interest: Martina Tedesco Conflict of interest: Giulia Pazzola Conflict of interest: Paola Tomietto Conflict of interest: Marco Pellecchio Conflict of interest: Chiara Marvisi Conflict of interest: Federica Maritati Conflict of interest: Alessandra Palmisano Conflict of interest: Christian Dejaco Conflict of interest: Johann Willeit Conflict of interest: Stefan Kiechl Conflict of interest: Iacopo Olivotto Conflict of interest: Peter Willeit Conflict of interest: Domenico Prisco Conflict of interest: Augusto Vaglio Conflict of interest: Giacomo Emmi
Published: 2020

27. Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)

Author: Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Sinico, Renato Alberto, Schiavon, Franco, Monti, Sara, Bozzolo, Enrica Paola, Franceschini, Franco, Govoni, Marcello, Lunardi, Claudio, Guida, Giuseppe, Lopalco, Giuseppe, Paolazzi, Giuseppe, Vacca, Angelo, Gregorini, Gina, Leccese, Pietro, Piga, Matteo, Conti, Fabrizio, Fraticelli, Paolo, Quartuccio, Luca, Alberici, Federico, Salvarani, Carlo, Bettio, Silvano, Negrini, Simone, Selmi, Carlo, Sciascia, Savino, Moroni, Gabriella, Colla, Loredana, Manno, Carlo, Urban, Maria Letizia, Vannacci, Alfredo, Pozzi, Maria Rosa, Fabbrini, Paolo, Polti, Stefano, Felicetti, Mara, Marchi, Maria Rita, Padoan, Roberto, Delvino, Paolo, Caporali, Roberto, Montecucco, Carlomaurizio, Dagna, Lorenzo, Cariddi, Adriana, Toniati, Paola, Tamanini, Silvia, Furini, Federica, Bortoluzzi, Alessandra, Tinazzi, Elisa, Delfino, Lorenzo, Badiu, Iuliana, Rolla, Giovanni, Venerito, Vincenzo, Iannone, Florenzo, Berti, Alvise, Bortolotti, Roberto, Racanelli, Vito, Jeannin, Guido, Padula, Angela, Cauli, Alberto, Priori, Roberta, Gabrielli, Armando, Bond, Milena, Tedesco, Martina, Pazzola, Giulia, Tomietto, Paola, Pellecchio, Marco, Marvisi, Chiara, Maritati, Federica, Palmisano, Alessandra, Dejaco, Christian, Willeit, Johann, Kiechl, Stefan, Olivotto, Iacopo, Willeit, Peter, Prisco, Domenico, Vaglio, Augusto, Emmi, Giacomo, Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Sinico, Renato Alberto, Schiavon, Franco, Monti, Sara, Bozzolo, Enrica Paola, Franceschini, Franco, Govoni, Marcello, Lunardi, Claudio, Guida, Giuseppe, Lopalco, Giuseppe, Paolazzi, Giuseppe, Vacca, Angelo, Gregorini, Gina, Leccese, Pietro, Piga, Matteo, Conti, Fabrizio, Fraticelli, Paolo, Quartuccio, Luca, Alberici, Federico, Salvarani, Carlo, Bettio, Silvano, Negrini, Simone, Selmi, Carlo, Sciascia, Savino, Moroni, Gabriella, Colla, Loredana, Manno, Carlo, Urban, Maria Letizia, Vannacci, Alfredo, Pozzi, Maria Rosa, Fabbrini, Paolo, Polti, Stefano, Felicetti, Mara, Marchi, Maria Rita, Padoan, Roberto, Delvino, Paolo, Caporali, Roberto, Montecucco, Carlomaurizio, Dagna, Lorenzo, Cariddi, Adriana, Toniati, Paola, Tamanini, Silvia, Furini, Federica, Bortoluzzi, Alessandra, Tinazzi, Elisa, Delfino, Lorenzo, Badiu, Iuliana, Rolla, Giovanni, Venerito, Vincenzo, Iannone, Florenzo, Berti, Alvise, Bortolotti, Roberto, Racanelli, Vito, Jeannin, Guido, Padula, Angela, Cauli, Alberto, Priori, Roberta, Gabrielli, Armando, Bond, Milena, Tedesco, Martina, Pazzola, Giulia, Tomietto, Paola, Pellecchio, Marco, Marvisi, Chiara, Maritati, Federica, Palmisano, Alessandra, Dejaco, Christian, Willeit, Johann, Kiechl, Stefan, Olivotto, Iacopo, Willeit, Peter, Prisco, Domenico, Vaglio, Augusto, and Emmi, Giacomo
Published: 2021

28. Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Author: Papo, M, Sinico, R, Teixeira, V, Venhoff, N, Urban, M, Iudici, M, Mahrhold, J, Locatelli, F, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Troilo, A, Thiel, J, Hellmich, B, Monti, S, Montecucco, C, Salvarani, C, Kahn, J, Bonnotte, B, Durel, C, Puéchal, X, Mouthon, L, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, Matthias, Sinico, Renato A, Teixeira, Vítor, Venhoff, Nils, Urban, Maria-Letizia, Iudici, Michele, Mahrhold, Juliane, Locatelli, Francesco, Cassone, Giulia, Schiavon, Franco, Seeliger, Benjamin, Neumann, Thomas, Kroegel, Claus, Groh, Matthieu, Marvisi, Chiara, Samson, Maxime, Barba, Thomas, Jayne, David, Troilo, Arianna, Thiel, Jens, Hellmich, Bernhard, Monti, Sara, Montecucco, Carlomaurizio, Salvarani, Carlo, Kahn, Jean-Emmanuel, Bonnotte, Bernard, Durel, Cécile-Audrey, Puéchal, Xavier, Mouthon, Luc, Guillevin, Loïc, Emmi, Giacomo, Vaglio, Augusto, Terrier, Benjamin, Papo, M, Sinico, R, Teixeira, V, Venhoff, N, Urban, M, Iudici, M, Mahrhold, J, Locatelli, F, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Troilo, A, Thiel, J, Hellmich, B, Monti, S, Montecucco, C, Salvarani, C, Kahn, J, Bonnotte, B, Durel, C, Puéchal, X, Mouthon, L, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, Matthias, Sinico, Renato A, Teixeira, Vítor, Venhoff, Nils, Urban, Maria-Letizia, Iudici, Michele, Mahrhold, Juliane, Locatelli, Francesco, Cassone, Giulia, Schiavon, Franco, Seeliger, Benjamin, Neumann, Thomas, Kroegel, Claus, Groh, Matthieu, Marvisi, Chiara, Samson, Maxime, Barba, Thomas, Jayne, David, Troilo, Arianna, Thiel, Jens, Hellmich, Bernhard, Monti, Sara, Montecucco, Carlomaurizio, Salvarani, Carlo, Kahn, Jean-Emmanuel, Bonnotte, Bernard, Durel, Cécile-Audrey, Puéchal, Xavier, Mouthon, Luc, Guillevin, Loïc, Emmi, Giacomo, Vaglio, Augusto, and Terrier, Benjamin
Abstract: OBJECTIVES: Only a third of patients with eosinophilic granulomatosis with polyangiitis (EGPA) are ANCA-positive, mainly directed against MPO. ANCA directed against PR3 are rarely found in EGPA. We aimed to examine the significance of PR3-ANCA in EGPA. METHODS: We set up a retrospective European multicentre cohort including 845 patients. Baseline characteristics and outcomes were analysed and compared according to ANCA status. RESULTS: ANCA status was available for 734 patients: 508 (69.2%) ANCA-negative, 210 (28.6%) MPO-ANCA and 16 (2.2%) PR3-ANCA. At baseline, PR3-ANCA patients, compared with those with MPO-ANCA and ANCA-negative, less frequently had active asthma (69% vs 91% and 93%, P = 0.003, respectively) and peripheral neuropathy (31% vs 71% and 47%, P < 0.0001), more frequently had cutaneous manifestations (63% vs 38% and 34%, P = 0.03) and pulmonary nodules (25% vs 10% and 8%, P = 0.046), and lower median eosinophil count (1450 vs 5400 and 3224/mm3, P < 0.0001). Vasculitis relapse-free survival was shorter for PR3-ANCA (hazard ratio 6.05, P = 0.005) and MPO-ANCA patients (hazard ratio 1.88, P = 0.0002) compared with ANCA-negative patients. CONCLUSION: PR3-ANCA EGPA patients differ from those with MPO-ANCA and negative ANCA, and share clinical features with granulomatosis with polyangiitis. This suggests that PR3-ANCA EGPA could be a particular form of PR3-ANCA-associated vasculitis.
Published: 2021

29. Séquelles à long terme au cours de la granulomatose éosinophilique avec polyangéite : données issues d’une étude rétrospective multicentrique de 845 patients

Author: Papo, M., primary, Sinico, R.A., additional, Teixeira, V., additional, Urban, M.L., additional, Mahrhold, J., additional, Monti, S., additional, Cassone, G., additional, Schiavon, F., additional, Seeliger, B., additional, Neumann, T., additional, Kroegel, C., additional, Jayne, D., additional, Hellmich, B., additional, Salvarani, C., additional, Kahn, J.E., additional, Durel, C.A., additional, Vaglio, A., additional, Emmi, G., additional, Guillevin, L., additional, and Terrier, B., additional
Published: 2020
Full Text: View/download PDF

30. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients

Author: Zen, M., primary, Fuzzi, E., additional, Astorri, D., additional, Saccon, F., additional, Padoan, R., additional, Ienna, L., additional, Cozzi, G., additional, Depascale, R., additional, Zanatta, E., additional, Gasparotto, M., additional, Benvenuti, F., additional, Bindoli, S., additional, Gatto, M., additional, Felicetti, M., additional, Ortolan, A., additional, Campaniello, D., additional, Larosa, M., additional, Lorenzin, M., additional, Ramonda, R., additional, Sfriso, P., additional, Schiavon, F., additional, Iaccarino, L., additional, and Doria, A., additional
Published: 2020
Full Text: View/download PDF

31. FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS

Author: Monti, S., primary, Dagna, L., additional, Campochiaro, C., additional, Tomelleri, A., additional, Zanframundo, G., additional, Klersy, C., additional, Muratore, F., additional, Boiardi, L., additional, Padoan, R., additional, Felicetti, M., additional, Schiavon, F., additional, Bond, M., additional, Berti, A., additional, Bortolotti, R., additional, Nannini, C., additional, Cantini, F., additional, Giollo, A., additional, Conticini, E., additional, Gattamelata, A., additional, Priori, R., additional, Quartuccio, L., additional, Treppo, E., additional, Emmi, G., additional, Finocchi, M., additional, Cassone, G., additional, Hoxha, A., additional, Foti, R., additional, Colaci, M., additional, Caporali, R., additional, Salvarani, C., additional, and Montecucco, C., additional
Published: 2020
Full Text: View/download PDF

32. FRI0214 PERSISTENT LOW-GRADE FDG-PET VASCULAR INFLAMMATION IN REMITTED LVV-GCA PATIENTS IS ASSOCIATED TO A SIGNIFICANT HIGH RISK OF RELAPSE

Author: Padoan, R., primary, Tomelleri, A., additional, Felicetti, M., additional, Campochiaro, C., additional, Baldissera, E., additional, Crimì, F., additional, Zucchetta, P., additional, Cecchin, D., additional, Picchio, M., additional, Dagna, L., additional, Doria, A., additional, and Schiavon, F., additional
Published: 2020
Full Text: View/download PDF

33. SAT0243 SUBPHENOTYPES IN POLYARTERITIS NODOSA (PAN): TARGET ORGAN ASSOCIATIONS OF A WORLDWIDE COLLABORATION STUDY

Author: Karadag, O., primary, Bolek, E. C., additional, Furuta, S., additional, Emmi, G., additional, Hocevar, A., additional, Hinojosa-Azaola, A., additional, Mohammad, A. J., additional, Ugurlu, S., additional, Alibaz-Oner, F., additional, Yazici, A., additional, Quartuccio, L., additional, Bozzolo, E., additional, Dagna, L., additional, Ramirez, G. A., additional, Cantarini, L., additional, Gregorini, G., additional, Guido, J., additional, Monti, S., additional, Martin-Nares, E., additional, Schiavon, F., additional, Padoan, R., additional, Kono, H., additional, Vaglio, A., additional, Kiliçkap, S., additional, Ertenli, A. İ., additional, Direskeneli, H., additional, Özen, S., additional, and Jayne, D., additional
Published: 2020
Full Text: View/download PDF

34. SAT0245 RENAL INVOLVEMENT AT ONSET IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS: A MAJOR INDEPENDENT RISK FACTOR FOR RENAL RELAPSE

Author: Felicetti, M., primary, Ortolan, A., additional, Frigo, A. C., additional, Padoan, R., additional, Gasparotto, M., additional, Lorenzin, M., additional, Doria, A., additional, Ramonda, R., additional, and Schiavon, F., additional
Published: 2020
Full Text: View/download PDF

35. La granulomatose éosinophilique avec polyangéite (Churg-Strauss) avec positivité des ANCA-PR3 existe-t-elle réellement ?

Author: Papo, M., primary, Sinico, R.A., additional, Teixeira, V., additional, Urban, M.L., additional, Mahrhold, J., additional, Monti, S., additional, Cassone, G., additional, Schiavon, F., additional, Seeliger, B., additional, Neumann, T., additional, Kroegel, C., additional, Groh, M., additional, Samson, M., additional, Jayne, D., additional, Hellmich, B., additional, Salvarani, C., additional, Guillevin, L., additional, Emmi, G., additional, Vaglio, A., additional, and Terrier, B., additional
Published: 2019
Full Text: View/download PDF

36. Thrombin genaration and microparticles plasma levels in patients with vasculitis: OC-TU-086

Author: Castelli, M, Spiezia, L, Rossetto, V, Carraro, V, Radu, C, Schiavon, F, Todesco, S, Pagnan, A, and Simioni, P
Published: 2009
Full Text: View/download PDF

37. Ionizing radiations in pregnancy and teratogenesis: A review of literature

Author: De Santis, M., Di Gianantonio, E., Straface, G., Cavaliere, A.F., Caruso, A., Schiavon, F., Berletti, R., and Clementi, M.
Published: 2005
Full Text: View/download PDF

38. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS

Author: Papo, M, Sinico, Ra, Teixeira, V, Urban, Ml, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Hellmich, B, Montecucco, C, Salvarani, C, Kahn, Je, Bonnotte, B, Durel, Ca, Mouthon, L, Puechal, X, Guillevin, L, Emmi, G, Vaglio, A, and Terrier, B
Published: 2019

39. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS

Author: Papo, M, Sinico, Ra, Teixeira, V, Urban, Ml, Mahrhold, J, Monti, S, Cassone, G, Schiavon, F, Seeliger, B, Neumann, T, Kroegel, C, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Hellmich, B, Montecucco, C, Salvarani, C, Kahn, Je, Bonnotte, B, Durel, Ca, Puechal, X, Mouthon, L, Guillevin, L, Emmi, G, Vaglio, A, and Terrier, B
Published: 2019

40. No differences in nasal tissue inflammatory cells and adhesion molecules (iCAM-1 and vCAM-1) comparing EGPA with eosinophilic chronic sinusitis with polyposis

Author: Brescia, G, Schiavon, F, Nicolè, L, Zanoletti, E, Zanotti, C, Padoan, R, Felicetti, M, Parrino, D, Cinetto, F, Cangiano, D, Giacomelli, L, Cappellesso, R, Martini, A, Fassina, A, and Marioni, G.
Published: 2019

41. 117. Prediction of Long-Term Evolutionary Profiles in Eosinophilic Granulomatosis with Polyangiitis (Churg– Strauss) Based on Baseline and Follow-Up Characteristics

Author: Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Cassone, G, Schiavon, F, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Bonnotte, B, Durel, C, Cohen, P, Puéchal, X, Mouthon, L, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, Matthias, Sinico, Renato, Teixeira, Vítor, Urban, Maria Letizia, Mahrhold, Juliane, Cassone, Giulia, Schiavon, Franco, Groh, Matthieu, Marvisi, Chiara, Samson, Maxime, Barba, Thomas, Jayne, David, Hellmich, Bernhard, Salvarani, Carlo, Kahn, Jean-Emmanuel, Bonnotte, Bernard, Durel, Cécile-Audrey, Cohen, Pascal, Puéchal, Xavier, Mouthon, Luc, Guillevin, Loïc, Emmi, Giacomo, Vaglio, Augusto, Terrier, Benjamin, Papo, M, Sinico, R, Teixeira, V, Urban, M, Mahrhold, J, Cassone, G, Schiavon, F, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Bonnotte, B, Durel, C, Cohen, P, Puéchal, X, Mouthon, L, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, Matthias, Sinico, Renato, Teixeira, Vítor, Urban, Maria Letizia, Mahrhold, Juliane, Cassone, Giulia, Schiavon, Franco, Groh, Matthieu, Marvisi, Chiara, Samson, Maxime, Barba, Thomas, Jayne, David, Hellmich, Bernhard, Salvarani, Carlo, Kahn, Jean-Emmanuel, Bonnotte, Bernard, Durel, Cécile-Audrey, Cohen, Pascal, Puéchal, Xavier, Mouthon, Luc, Guillevin, Loïc, Emmi, Giacomo, Vaglio, Augusto, and Terrier, Benjamin
Published: 2019

42. 354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS

Author: Papo, M, Sinico, A, Teixeira, V, Urban, M, Mahrhold, J, Cassone, G, Schiavon, F, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Bonnotte, B, Durel, C, Cohen, P, Puéchal, X, Mouthon, L, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, Matthias, Sinico, Alberto, Teixeira, Vítor, Urban, Maria Letizia, Mahrhold, Juliane, Cassone, Giulia, Schiavon, Franco, Groh, Matthieu, Marvisi, Chiara, Samson, Maxime, Barba, Thomas, Jayne, David, Hellmich, Bernhard, Salvarani, Carlo, Kahn, Jean-Emmanuel, Bonnotte, Bernard, Durel, Cécile-Audrey, Cohen, Pascal, Puéchal, Xavier, Mouthon, Luc, Guillevin, Loïc, Emmi, Giacomo, Vaglio, Augusto, Terrier, Benjamin, Papo, M, Sinico, A, Teixeira, V, Urban, M, Mahrhold, J, Cassone, G, Schiavon, F, Groh, M, Marvisi, C, Samson, M, Barba, T, Jayne, D, Hellmich, B, Salvarani, C, Kahn, J, Bonnotte, B, Durel, C, Cohen, P, Puéchal, X, Mouthon, L, Guillevin, L, Emmi, G, Vaglio, A, Terrier, B, Papo, Matthias, Sinico, Alberto, Teixeira, Vítor, Urban, Maria Letizia, Mahrhold, Juliane, Cassone, Giulia, Schiavon, Franco, Groh, Matthieu, Marvisi, Chiara, Samson, Maxime, Barba, Thomas, Jayne, David, Hellmich, Bernhard, Salvarani, Carlo, Kahn, Jean-Emmanuel, Bonnotte, Bernard, Durel, Cécile-Audrey, Cohen, Pascal, Puéchal, Xavier, Mouthon, Luc, Guillevin, Loïc, Emmi, Giacomo, Vaglio, Augusto, and Terrier, Benjamin
Published: 2019

43. 135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS

Author: Emmi, G, Bettiol, A, Urban, M, Sinico, R, Schiavon, F, Caporali, R, Prisco, D, Vaglio, A, Emmi, Giacomo, Bettiol, Alessandra, Urban, Maria Letizia, Sinico, Renato, Schiavon, Franco, Caporali, Roberto, Prisco, Domenico, Vaglio, Augusto, Emmi, G, Bettiol, A, Urban, M, Sinico, R, Schiavon, F, Caporali, R, Prisco, D, Vaglio, A, Emmi, Giacomo, Bettiol, Alessandra, Urban, Maria Letizia, Sinico, Renato, Schiavon, Franco, Caporali, Roberto, Prisco, Domenico, and Vaglio, Augusto
Published: 2019

44. Transient joint effusion: a forgotten side effect of high dose corticosteroid treatment

Author: Schiavon, F
Published: 2003

45. Intravenous immunoglobulins control scleromyxoedema

Author: Righi, A, Schiavon, F, Jablonska, S, Doria, A, Blasczyk, M, Rondinone, R, Todesco, S, and Cerinic, Matucci M
Published: 2002

46. Morphologic Study of Microcirculation in Acromegaly by Capillaroscopy*

Author: Schiavon, F, Maffei, P, Martini, C, De Carlo, E, Fais, C, Todesco, S, and Sicolo, N
Published: 1999

47. P.02.35 INTESTINAL INVOLVEMENT IN WEGENER'S GRANULOMATOSIS MIMICKING AN INFLAMMATORY BOWEL DISEASE: A CASE REPORT

Author: Pelizzaro, F., primary, Ghisa, M., additional, Bareberio, B., additional, Barbuscio, I., additional, Coletta, M. Della, additional, Cocconcelli, E., additional, Schiavon, F., additional, Savarino, E.V., additional, Farinati, F., additional, and Galeazzi, F., additional
Published: 2019
Full Text: View/download PDF

48. Caractéristiques au diagnostic et profils évolutifs des patients atteints de granulomatose éosinophilique avec polyangéite (Churg-Strauss) : données d’une étude rétrospective collaborative européenne

Author: Papo, M., primary, Emmi, G., additional, Schiavon, F., additional, Groh, M., additional, Samson, M., additional, Kahn, J.E., additional, Sinico, R.A., additional, Puéchal, X., additional, Mouthon, L., additional, Guillevin, L., additional, Vaglio, A., additional, and Terrier, B., additional
Published: 2018
Full Text: View/download PDF

49. Efficacité des traitements utilisés chez les patients suivis pour une granulomatose éosinophilique avec polyangéite (Churg-Strauss) en fonction du profil évolutif de la maladie : données d’une étude rétrospective collaborative européenne

Author: Papo, M., primary, Emmi, G., additional, Schiavon, F., additional, Groh, M., additional, Kahn, J.E., additional, Sinico, R.A., additional, Samson, M., additional, Puéchal, X., additional, Mouthon, L., additional, Guillevin, L., additional, Vaglio, A., additional, and Terrier, B., additional
Published: 2018
Full Text: View/download PDF

50. Fibroblastic rheumatism: a fifteen-year followup study

Author: Schiavon, F., Punzi, L., and Todesco, S.
Published: 1998

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

349 results on '"Schiavon, F"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources